Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01781468 · ClinicalTrials.gov registry record · Phase 3
Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 328
- Enrollment target
NCT01781468 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 328 participants.
The verdict
NCT01781468, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 328 participants
- Enrollment target
Study Summary
This randomized phase III trial studies armodafinil to see how well it works in reducing cancer-related fatigue in patients with high grade glioma. Armodafinil may help relieve fatigue in patients with high grade glioma.
Interventions
- OTHER Placebo
- DRUG armodafinil 150 mg
- DRUG armodafinil 250 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2013-06-21 |
| Est. Completion | 2019-12-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01781468
The ClinicalTrials.gov registry entry for NCT01781468 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01781468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01781468 about?
NCT01781468 is a clinical study titled "Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma". This randomized phase III trial studies armodafinil to see how well it works in reducing cancer-related fatigue in patients with high grade glioma. Armodafinil may help relieve fatigue in patients with high grade glioma.
What is the current status of trial NCT01781468?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 328 participants. The study started on 2013-06-21. Estimated completion is 2019-12-15.
What interventions are being tested in trial NCT01781468?
The interventions under investigation include: Placebo (OTHER), armodafinil 150 mg (DRUG), armodafinil 250 mg (DRUG).
Who is sponsoring clinical trial NCT01781468?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.